Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozone Therapy in Refractory Ischemic Heart Disease
NCT03660657Phase 3
Key facts
- Status
- Terminated
- Start
- Feb 2020
- Primary completion
- Nov 2020
- Countries
- 1
- Modality
- Inhalation Devices
- Conditions
- ischemic heart disease (IHD)
01
Overview
Phase 3, randomised, triple-blind trial of medical ozonated water in ischemic heart disease (IHD). Primary endpoint: Minnesota Living with Heart Failure Questionnaire at 16 weeks. Started Feb 2020; status: terminated.
02
Design
- Study design
- RandomizedTriple-blind
03
Who it enrols
Adults with refractory NYHA Class III-IV ischemic heart disease, LVEF < 40%, who are not candidates for further surgical or percutaneous procedures.
04
Endpoints
Primary
Minnesota Living with Heart Failure Questionnaire
Beyond the preview
Go deeper on NCT03660657.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03660657.